| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drugs, Chinese Herbal | 3 | 2020 | 48 | 1.600 |
Why?
|
| Salvia | 2 | 2020 | 3 | 1.400 |
Why?
|
| Chromosome Aberrations | 6 | 2015 | 1960 | 1.210 |
Why?
|
| Chromosomes, Human | 3 | 2017 | 295 | 1.140 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2020 | 249 | 1.110 |
Why?
|
| Myelodysplastic Syndromes | 9 | 2014 | 2979 | 1.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 461 | 1.070 |
Why?
|
| Trisomy | 3 | 2014 | 231 | 1.020 |
Why?
|
| RAW 264.7 Cells | 3 | 2020 | 57 | 0.960 |
Why?
|
| Sesquiterpenes | 3 | 2018 | 68 | 0.920 |
Why?
|
| Translocation, Genetic | 4 | 2018 | 1245 | 0.880 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2014 | 197 | 0.860 |
Why?
|
| Diterpenes | 3 | 2017 | 111 | 0.830 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2022 | 46 | 0.830 |
Why?
|
| Lymphoma, B-Cell | 4 | 2022 | 895 | 0.780 |
Why?
|
| NF-kappa B | 6 | 2020 | 1549 | 0.780 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2022 | 810 | 0.730 |
Why?
|
| Anthozoa | 2 | 2017 | 6 | 0.730 |
Why?
|
| Aristolochia | 2 | 2018 | 3 | 0.710 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 92 | 0.710 |
Why?
|
| Neoplasms, Second Primary | 5 | 2015 | 1350 | 0.700 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2018 | 52 | 0.670 |
Why?
|
| In Situ Hybridization, Fluorescence | 9 | 2022 | 2232 | 0.630 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2022 | 6915 | 0.580 |
Why?
|
| Gene Rearrangement | 5 | 2022 | 783 | 0.580 |
Why?
|
| Bone Marrow | 6 | 2015 | 2358 | 0.570 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2015 | 259 | 0.560 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2021 | 801 | 0.550 |
Why?
|
| Lignans | 1 | 2015 | 15 | 0.540 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2014 | 402 | 0.530 |
Why?
|
| Heme Oxygenase-1 | 1 | 2015 | 54 | 0.530 |
Why?
|
| Benzofurans | 1 | 2015 | 38 | 0.520 |
Why?
|
| Chromosome Deletion | 2 | 2017 | 1005 | 0.520 |
Why?
|
| Immunophenotyping | 6 | 2018 | 1681 | 0.500 |
Why?
|
| Polycythemia Vera | 1 | 2017 | 238 | 0.490 |
Why?
|
| Karyotyping | 5 | 2018 | 1022 | 0.480 |
Why?
|
| Hematologic Neoplasms | 3 | 2021 | 1870 | 0.460 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 215 | 0.450 |
Why?
|
| Inflammation | 2 | 2020 | 2522 | 0.450 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2014 | 426 | 0.450 |
Why?
|
| Myeloid Cells | 1 | 2014 | 269 | 0.450 |
Why?
|
| Antigens, CD34 | 2 | 2012 | 593 | 0.440 |
Why?
|
| Flow Cytometry | 4 | 2015 | 3033 | 0.420 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1664 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2012 | 181 | 0.420 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2017 | 1538 | 0.410 |
Why?
|
| Macrophages | 2 | 2017 | 1304 | 0.410 |
Why?
|
| Pancytopenia | 1 | 2012 | 120 | 0.410 |
Why?
|
| Gene Amplification | 1 | 2014 | 731 | 0.400 |
Why?
|
| Myeloproliferative Disorders | 1 | 2018 | 767 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 272 | 0.390 |
Why?
|
| Megakaryocytes | 1 | 2011 | 104 | 0.380 |
Why?
|
| Selaginellaceae | 1 | 2009 | 2 | 0.360 |
Why?
|
| Indole Alkaloids | 1 | 2009 | 7 | 0.350 |
Why?
|
| Lymphocytes | 1 | 2014 | 1234 | 0.350 |
Why?
|
| Basophils | 1 | 2009 | 38 | 0.350 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 941 | 0.340 |
Why?
|
| Oxidative Stress | 1 | 2015 | 1129 | 0.340 |
Why?
|
| Pyrrolidines | 1 | 2009 | 113 | 0.340 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 29902 | 0.330 |
Why?
|
| Molecular Structure | 6 | 2017 | 515 | 0.320 |
Why?
|
| Medicine, Chinese Traditional | 2 | 2018 | 30 | 0.320 |
Why?
|
| Chromosome Inversion | 2 | 2022 | 182 | 0.310 |
Why?
|
| Aged | 21 | 2021 | 70117 | 0.300 |
Why?
|
| Middle Aged | 23 | 2021 | 86204 | 0.300 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 482 | 0.290 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2015 | 2527 | 0.290 |
Why?
|
| Male | 27 | 2021 | 123000 | 0.280 |
Why?
|
| Adult | 21 | 2021 | 77950 | 0.270 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 1242 | 0.270 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 3552 | 0.270 |
Why?
|
| Lymphoma | 1 | 2014 | 1467 | 0.260 |
Why?
|
| Humans | 35 | 2022 | 261506 | 0.250 |
Why?
|
| Plant Extracts | 2 | 2017 | 215 | 0.250 |
Why?
|
| Neurons | 1 | 2015 | 2287 | 0.250 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 505 | 0.250 |
Why?
|
| Female | 24 | 2021 | 141928 | 0.240 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 6550 | 0.240 |
Why?
|
| Mutation | 5 | 2018 | 15179 | 0.230 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2012 | 2390 | 0.220 |
Why?
|
| Bone Marrow Cells | 3 | 2015 | 943 | 0.220 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2015 | 71 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 639 | 0.210 |
Why?
|
| Survival Rate | 6 | 2017 | 12221 | 0.210 |
Why?
|
| I-kappa B Proteins | 3 | 2017 | 170 | 0.210 |
Why?
|
| Oncogene Fusion | 1 | 2021 | 63 | 0.200 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2014 | 461 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2022 | 254 | 0.190 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 2796 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2012 | 185 | 0.180 |
Why?
|
| Molecular Conformation | 2 | 2017 | 171 | 0.180 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 14289 | 0.170 |
Why?
|
| Cell Survival | 2 | 2016 | 3045 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2016 | 1493 | 0.170 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 2283 | 0.170 |
Why?
|
| Caspases | 1 | 2001 | 661 | 0.170 |
Why?
|
| Aldehydes | 1 | 2018 | 44 | 0.170 |
Why?
|
| Sequence Deletion | 1 | 2022 | 875 | 0.170 |
Why?
|
| Cytogenetics | 1 | 2018 | 149 | 0.170 |
Why?
|
| Apoptosis | 4 | 2015 | 7591 | 0.160 |
Why?
|
| Lipopolysaccharides | 2 | 2017 | 558 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2020 | 11965 | 0.160 |
Why?
|
| Croton | 1 | 2017 | 2 | 0.160 |
Why?
|
| Plant Components, Aerial | 1 | 2017 | 3 | 0.160 |
Why?
|
| Cephalotaxus | 1 | 2017 | 1 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 2 | 2017 | 848 | 0.150 |
Why?
|
| Crotalaria | 1 | 2016 | 2 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 755 | 0.140 |
Why?
|
| Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2016 | 13 | 0.140 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2016 | 30 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 548 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 7222 | 0.140 |
Why?
|
| Plant Stems | 1 | 2015 | 8 | 0.140 |
Why?
|
| Prognosis | 6 | 2015 | 21713 | 0.130 |
Why?
|
| Young Adult | 6 | 2021 | 21445 | 0.130 |
Why?
|
| Fibrosis | 1 | 2018 | 793 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 423 | 0.130 |
Why?
|
| Models, Molecular | 2 | 2017 | 1732 | 0.120 |
Why?
|
| China | 1 | 2016 | 606 | 0.120 |
Why?
|
| Sarcoma, Myeloid | 1 | 2015 | 95 | 0.120 |
Why?
|
| Disease Progression | 2 | 2018 | 6682 | 0.120 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2015 | 115 | 0.120 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 299 | 0.120 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10001 | 0.120 |
Why?
|
| Mice | 7 | 2020 | 34495 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2014 | 135 | 0.120 |
Why?
|
| Animals | 9 | 2020 | 59536 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 15862 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2014 | 231 | 0.120 |
Why?
|
| Glutamic Acid | 1 | 2015 | 309 | 0.120 |
Why?
|
| Recurrence | 1 | 2022 | 4758 | 0.120 |
Why?
|
| Meliaceae | 1 | 2013 | 1 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2015 | 362 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2021 | 16273 | 0.110 |
Why?
|
| Cell Death | 1 | 2015 | 671 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 317 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 1130 | 0.110 |
Why?
|
| Triterpenes | 1 | 2013 | 61 | 0.110 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 43 | 0.110 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 2138 | 0.110 |
Why?
|
| Color | 1 | 2012 | 66 | 0.110 |
Why?
|
| Pyrazines | 1 | 2015 | 495 | 0.110 |
Why?
|
| Antioxidants | 1 | 2015 | 507 | 0.100 |
Why?
|
| Mastocytosis, Systemic | 1 | 2013 | 110 | 0.100 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2012 | 173 | 0.100 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2011 | 58 | 0.100 |
Why?
|
| Risk | 2 | 2014 | 1972 | 0.100 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2012 | 247 | 0.100 |
Why?
|
| Mast Cells | 1 | 2013 | 223 | 0.100 |
Why?
|
| Plasma Cells | 1 | 2012 | 192 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2014 | 1391 | 0.100 |
Why?
|
| I-kappa B Kinase | 2 | 2001 | 250 | 0.090 |
Why?
|
| Risk Factors | 3 | 2017 | 17523 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 987 | 0.090 |
Why?
|
| Classification | 1 | 2009 | 41 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2013 | 994 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2015 | 9180 | 0.090 |
Why?
|
| Hippocampus | 1 | 2015 | 915 | 0.090 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2009 | 118 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2015 | 3536 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 4892 | 0.090 |
Why?
|
| Erythroblasts | 1 | 2008 | 24 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2009 | 96 | 0.080 |
Why?
|
| Phenotype | 3 | 2016 | 6295 | 0.080 |
Why?
|
| Erythroid Precursor Cells | 1 | 2008 | 61 | 0.080 |
Why?
|
| World Health Organization | 1 | 2009 | 316 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 110 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2011 | 588 | 0.080 |
Why?
|
| Cytokines | 1 | 2017 | 2809 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 6207 | 0.080 |
Why?
|
| Biopsy | 2 | 2016 | 3443 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 566 | 0.080 |
Why?
|
| Child | 4 | 2017 | 29154 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2012 | 1385 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 1910 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 4744 | 0.070 |
Why?
|
| Age Factors | 2 | 2013 | 5377 | 0.070 |
Why?
|
| Crystallography, X-Ray | 2 | 2017 | 627 | 0.070 |
Why?
|
| Remission Induction | 1 | 2011 | 3569 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 548 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 5539 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1443 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2014 | 37905 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 7548 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 4821 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 301 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2009 | 1620 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 4971 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4298 | 0.060 |
Why?
|
| Nitric Oxide | 2 | 2017 | 644 | 0.060 |
Why?
|
| Adolescent | 4 | 2017 | 31252 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3230 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2009 | 1203 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 4988 | 0.050 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2001 | 25 | 0.050 |
Why?
|
| Cycloheximide | 1 | 2001 | 97 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2001 | 71 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2001 | 95 | 0.050 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2001 | 119 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2014 | 9244 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2002 | 1764 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2014 | 6869 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2009 | 1664 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2001 | 184 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 14889 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 14551 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2013 | 479 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2001 | 471 | 0.050 |
Why?
|
| Time Factors | 1 | 2014 | 12926 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2992 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2001 | 195 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2001 | 886 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 4757 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2001 | 798 | 0.040 |
Why?
|
| Point Mutation | 1 | 2001 | 769 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2001 | 1643 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1656 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 2063 | 0.040 |
Why?
|
| Phytochemicals | 1 | 2017 | 10 | 0.040 |
Why?
|
| Neoplasms | 2 | 2015 | 15193 | 0.040 |
Why?
|
| Biosynthetic Pathways | 1 | 2017 | 46 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 10331 | 0.040 |
Why?
|
| X-Ray Diffraction | 1 | 2017 | 168 | 0.040 |
Why?
|
| Spectrum Analysis | 1 | 2017 | 139 | 0.040 |
Why?
|
| Transfection | 1 | 2001 | 2944 | 0.040 |
Why?
|
| Tennessee | 1 | 2016 | 36 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 10035 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 125 | 0.030 |
Why?
|
| Dimerization | 1 | 2016 | 304 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 931 | 0.030 |
Why?
|
| Mothers | 1 | 2018 | 410 | 0.030 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2015 | 37 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2017 | 624 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 256 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 5395 | 0.030 |
Why?
|
| Cell Line | 2 | 2017 | 5114 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2001 | 4804 | 0.030 |
Why?
|
| Bortezomib | 1 | 2015 | 543 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 1963 | 0.030 |
Why?
|
| Abnormal Karyotype | 1 | 2013 | 100 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2017 | 5637 | 0.030 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 2012 | 11 | 0.030 |
Why?
|
| Models, Biological | 1 | 2001 | 3254 | 0.030 |
Why?
|
| Prednisone | 1 | 2015 | 984 | 0.030 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2012 | 73 | 0.030 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2002 | 136 | 0.030 |
Why?
|
| Melphalan | 1 | 2015 | 834 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2012 | 153 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2012 | 188 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2012 | 206 | 0.030 |
Why?
|
| Clone Cells | 1 | 2013 | 555 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2012 | 202 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 1742 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 509 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 4053 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 668 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 4938 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2012 | 577 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 864 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 882 | 0.020 |
Why?
|
| Cell Count | 1 | 2008 | 508 | 0.020 |
Why?
|
| Vidarabine | 1 | 2011 | 1341 | 0.020 |
Why?
|
| Rituximab | 1 | 2011 | 1528 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 6311 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3001 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1450 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 32848 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2002 | 226 | 0.010 |
Why?
|
| Phenylephrine | 1 | 2001 | 48 | 0.010 |
Why?
|
| Incidence | 1 | 2011 | 5673 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 461 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2001 | 68 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 3719 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 5047 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2001 | 198 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 13658 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 13310 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 1555 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2001 | 1338 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 6086 | 0.010 |
Why?
|
| United States | 1 | 2008 | 15433 | 0.010 |
Why?
|